Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 478,783
  • Shares Outstanding, K 53,376
  • Annual Sales, $ 27,460 K
  • Annual Income, $ -46,050 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.93
  • Price/Sales 17.44
  • Price/Cash Flow N/A
  • Price/Book 6.76

Options Overview Details

View History
  • Implied Volatility 69.61% ( -12.50%)
  • Historical Volatility 44.33%
  • IV Percentile 23%
  • IV Rank 17.13%
  • IV High 258.40% on 07/30/24
  • IV Low 30.57% on 06/06/24
  • Put/Call Vol Ratio 0.04
  • Today's Volume 670
  • Volume Avg (30-Day) 638
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 11,172
  • Open Int (30-Day) 19,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.39
  • Number of Estimates 3
  • High Estimate -0.37
  • Low Estimate -0.42
  • Prior Year -0.40
  • Growth Rate Est. (year over year) +2.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.67 +16.95%
on 10/25/24
9.27 -3.24%
on 11/20/24
+0.48 (+5.65%)
since 10/18/24
3-Month
6.61 +35.70%
on 10/01/24
9.27 -3.24%
on 11/20/24
+1.38 (+18.18%)
since 08/20/24
52-Week
4.20 +113.57%
on 07/05/24
9.27 -3.24%
on 11/20/24
+4.49 (+100.22%)
since 11/20/23

Most Recent Stories

More News
Zevra Therapeutics: Q3 Earnings Snapshot

Zevra Therapeutics: Q3 Earnings Snapshot

ZVRA : 8.97 (unch)
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates

ZVRA : 8.97 (unch)
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

ZVRA : 8.97 (unch)
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

ZVRA : 8.97 (unch)
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

ZVRA : 8.97 (unch)
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

ZVRA : 8.97 (unch)
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders

ZVRA : 8.97 (unch)
Zevra Stock Surges Close to 70% in 3 Months: Here's Why

Zevra Therapeutics, Inc. ZVRA obtained FDA approval for arimoclomol capsules for the treatment of Niemann-Pick disease type C (NPC) in September. The drug will be marketed under the brand name Miplyffa.The...

ZVRA : 8.97 (unch)
KRYS : 180.61 (+1.41%)
FULC : 2.99 (-0.66%)
ANIP : 54.30 (-1.45%)
Jaguar tells owners of older I-Pace electric SUVs to park them outdoors due to battery fire risk

Jaguar is telling owners of about 3,000 electric SUVs to park them outdoors and away from structures due to the risk of battery fires

ZVRA : 8.97 (unch)
$SPX : 5,917.11 (unch)
$DOWI : 43,408.47 (+0.32%)
$IUXX : 20,667.10 (-0.08%)
Zevra Therapeutics: Q2 Earnings Snapshot

Zevra Therapeutics: Q2 Earnings Snapshot

ZVRA : 8.97 (unch)

Business Summary

Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.

See More

Key Turning Points

3rd Resistance Point 9.82
2nd Resistance Point 9.54
1st Resistance Point 9.26
Last Price 8.97
1st Support Level 8.70
2nd Support Level 8.42
3rd Support Level 8.14

See More

52-Week High 9.27
Last Price 8.97
Fibonacci 61.8% 7.33
Fibonacci 50% 6.74
Fibonacci 38.2% 6.14
52-Week Low 4.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar